newsfilter
← Latest News
PR Newswire·

Gamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)

STOCKHOLM, Feb. 25, 2022 /PRNewswire/ -- Sobi® today announces that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant® to the National Medical Products Administration of China (NMPA). The indication is for treatment of adult and